Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345460 · ClinicalTrials.gov registry record · Phase 2
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02345460 is a Phase 2 study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 1 participants.
The verdict
NCT02345460, a Phase 2 study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This phase II trial studies how well combination chemotherapy works in treating patients with pancreatic cancer before undergoing surgery. Drugs used in chemotherapy, such as irinotecan hydrochloride, oxaliplatin, leucovorin calcium, and fluorouracil (FOLFIRINOX), work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Interventions
- DRUG Fluorouracil
- DRUG Oxaliplatin
- OTHER Laboratory Biomarker Analysis
- DRUG Irinotecan Hydrochloride
- DRUG Leucovorin Calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02345460
The ClinicalTrials.gov registry entry for NCT02345460 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fluorouracil is the first listed.
NCT02345460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02345460 about?
NCT02345460 is a clinical study titled "Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study". This phase II trial studies how well combination chemotherapy works in treating patients with pancreatic cancer before undergoing surgery. Drugs used in chemotherapy, such as irinotecan hydrochloride, oxaliplatin, leucovorin calcium, and fluorouracil (FOLFIRINOX), work in different ways to stop the ...
What is the current status of trial NCT02345460?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2015-09. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02345460?
The interventions under investigation include: Fluorouracil (DRUG), Oxaliplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Irinotecan Hydrochloride (DRUG), Leucovorin Calcium (DRUG).
Who is sponsoring clinical trial NCT02345460?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.